/
Current Therapy for Epilepsy Current Therapy for Epilepsy

Current Therapy for Epilepsy - PowerPoint Presentation

tatiana-dople
tatiana-dople . @tatiana-dople
Follow
401 views
Uploaded On 2017-11-30

Current Therapy for Epilepsy - PPT Presentation

J Layne Moore MD MPH Professor Neurology Wright State University Boonshoft School of Medicine Epilepsy A disease known from antiquity Initially thought to be from the attack of a spirit or demon ID: 611459

epilepsy ohio epileptics hospital ohio epilepsy hospital epileptics approved gallipolis therapy disease treatment bloodletting epileptic mutations international stigma rationale

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Current Therapy for Epilepsy" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Current Therapy for Epilepsy

J. Layne Moore, MD, MPH

Professor Neurology

Wright State University Boonshoft School of MedicineSlide2

Epilepsy

A disease known from antiquity

Initially thought to be from the attack of a spirit or demon

The name epilepsy is derived from the Greek word for “to attack” So a person does not “seizure” they are seized. Slide3

Rationale of Bloodletting

Bloodletting goes back 3000 years to the Egyptians.

To

appreciate the rationale for bloodletting one must first understand the paradigm of disease 2300 years ago in the time of Hippocrates

( circa 460

–370 BC).

Hippocrates believed that

existence was represented by the four basic elements—earth, air, fire, and water—which in humans were related to the four basic humors: blood, phlegm, black bile, yellow bile. 

.

 Slide4

HumorismSlide5
Slide6
Slide7

HumorismSlide8

Ohio Hospital for epileptics at Gallipolis OhioSlide9

Ohio Hospital for epileptics at Gallipolis OhioSlide10

Ohio Hospital for epileptics at Gallipolis OhioSlide11

Ohio Hospital for epileptics at Gallipolis OhioSlide12

The

commission consulted the foremost neurologists and alienists, at home and abroad, especially those experienced in the treatment of epilepsy, and submitted plans for the construction of 36 buildings for the segregation of epileptics in classified colonies, after the method of the Bielefeld Colony in Germany, as the best adapted for the welfare and treatment of those affected with epilepsy. Slide13

The Ohio Hospital for Epileptics

In 1892 the General Assembly passed an act changing the name of the institution from " The Asylum for Epileptics and Epileptic Insane " to " The Ohio Hospital for Epileptics."Slide14

http://

www.asylumprojects.org/index.php?title

=

Gallipolis_Epileptic_HospitalSlide15

Hans BergerSlide16

Science to problemSlide17

Wilder PenfieldSlide18
Slide19

PB

PHT

CBZ

VPA

FBM

GBP

LTG

FOS

TPM

TGB

3

rd

Generation

2nd Generation

OCBZ

LVT

ZNS

Antiepileptic Drug (AED) TherapySlide20

Newer AEDsSlide21

Rufinamide

developed in 2004 by Novartis and manufactured by Eisai. Approved for marketing 2008.

Approved as adjunct therapy for LGS

MOA uncertain perhaps sodium channelsSlide22

Lacosamide

Approved in 2008

Voltage-gated sodium channels

UCB

Approved for adjunct therapy for partial onsetSlide23

Ezogabine

A potassium channel

Therefore unique

Effective in many animal models of epilepsy

Studies underway in neuropathic pain, tinnitus and migraine

TID dosingSlide24

Perampanel

acts as a selective noncompetitive antagonist of AMPA receptors.

Being studied in Parkinson’s disease

Half-life 105 hours

95% protein boundSlide25

Brivaracetam

Approval may be early 2015

it is around 10 times more potent for some models of epilepsy than LevetiracetamSlide26

VNS

Approved for partial epilepsy 1997

Approved for depression 2005Slide27

Responsive Neurostimulator

Device

The RNS System utilizes a

neurostimulator

implanted in the skull with one or two leads implanted in the brain at focal points of seizuresSlide28

Quality of Life

Side-effects

Mood

Anxiety

Stigma

IsolationSlide29

Genetics

Severe childhood epilepsies: Large international study pinpoints synapse genes with major roles

September 25, 2014

Children's Hospital of Philadelphia

An international research team has identified gene mutations causing severe, difficult-to-treat forms of childhood epilepsy. Many of the mutations disrupt functioning in the synapse, the junction at which nerve cells intercommunicate.

 Slide30

What’s New at WSU/PHP?

Looking at new medicines (

Brivaracetam

) for the treatment of in hospital non-convulsive status epilepticus

Assessment of stigma experienced by our epilepsy patients in clinicSlide31

What’s Next?

Science

Hope